Is Your Paper Ready for JAMA? Journal of the American Medical Association Checklist

JAMA (Journal of the American Medical Association) publishes roughly 5-8% of submissions, desk-rejects about 90%, and enforces some of the strictest word limits and formatting requirements in medical publishing. Its impact factor sits around 55.0, making it one of the most cited general medical journals in the world.

For journal background beyond this readiness checklist, see the JAMA Journal of the American Medical Association journal hub.

JAMA's article types aren't suggestions. They're rigid categories with hard word limits, and editors won't reformat your paper for you. Submitting a 4,500-word manuscript as an Original Investigation (3,000-word cap) is an instant return. Here's what you're working with:

This is JAMA's flagship format. It's where the large RCTs, major cohort studies, and practice-changing observational research live. You get 3,000 words of text (excluding abstract, references, tables, and figures), up to 5 tables/figures combined, and roughly 40 references. The structured abstract has its own strict format with headings like Importance, Objective, Design/Setting/Participants, Main Outcomes and Measures, Results, and Conclusions and Relevance.

Three thousand words isn't much. If you're used to writing for specialty journals that give you 5,000-6,000 words, you'll need to cut aggressively. JAMA's editors don't consider this a constraint, they consider it a feature. If you can't tell the story in 3,000 words, the story probably isn't focused enough.

This is JAMA's most underused format, and honestly, it's where many authors should start. Research Letters are concise, allow 1 table or figure, and use a much tighter reference count than full Original Investigations. They don't require a structured abstract. They're meant for concise, practice-relevant findings that don't need the full Original Investigation treatment.

Here's what most people don't realize: a Research Letter in JAMA still carries the JAMA name and the JAMA JIF. For early-career researchers or for preliminary findings from a larger study, this format can be strategic. The review cycle tends to be shorter, and the desk rejection rate, while still high, isn't as brutal as for Original Investigations.

Viewpoints are 1,200 words with no abstract, up to 1 small table or figure, and 10 references. They're opinion pieces, but they aren't casual. JAMA Viewpoints need to make a specific argument about clinical practice, health policy, or medical education. They shouldn't read like editorials that could appear in any newspaper. The best ones propose something concrete: a policy change, a shift in clinical thinking, a reinterpretation of existing evidence.

You can submit Viewpoints without an invitation, which surprises many authors. However, the bar is high. You'll need genuine expertise and a genuinely fresh perspective.

These are invitation-only. Don't submit unsolicited reviews to JAMA. If you've got a review manuscript, JAMA Systematic Reviews or a JAMA Network specialty journal is where it should go. Editorials are commissioned to accompany specific published articles.

This is JAMA's catch-all for work that doesn't fit standard categories. Health policy analyses, methodological frameworks, and ethics analyses often land here. Word limit is 3,000 words, same as Original Investigations, but the format is more flexible. If your paper is important but isn't a traditional study, Special Communication might be the right fit.

I can't stress this enough. JAMA enforces word limits more strictly than almost any other major journal. The submission system counts your words, and manuscripts that exceed limits get bounced back automatically before an editor even sees them. This isn't PLOS ONE, where you can write 8,000 words and nobody blinks. JAMA's limits exist because the print edition has physical space constraints and because brevity is an editorial value.

Here's a practical breakdown:

If your Original Investigation draft is at 4,200 words, don't submit and hope they won't notice. They will. Cut it to 3,000 or consider whether some of the content belongs in a supplement.

About 90% of JAMA submissions don't make it past the editors' desks. That's not a typo. Nine out of ten papers get rejected without external review. The desk editors aren't being arbitrary, they're applying a ruthlessly consistent set of filters.

Filter 1: Article type and formatting compliance. Wrong article type, exceeded word limit, missing structured abstract headings, incomplete author disclosures. These are instant rejections that have nothing to do with your science.

Filter 2: Scope and audience match. JAMA's readers are primarily US-based generalist physicians. Research that matters only to subspecialists gets redirected to JAMA Network specialty journals. Work that's primarily relevant to non-US health systems may be a better fit for The Lancet or BMJ.

Filter 3: Clinical significance at scale. JAMA wants studies that could change practice for a large number of patients or affect health policy in a measurable way. A pilot study with 30 patients, no matter how well designed, won't pass this filter unless the preliminary findings are genuinely surprising.

Filter 4: Methodological red flags. The desk editors are trained to spot issues fast. Observational studies without pre-registration, clinical trials with surrogate endpoints when hard endpoints were feasible, systematic reviews that don't follow PRISMA, these trigger immediate skepticism.

If you've survived all four filters, congratulations. You're in the top 10%.

Here's where JAMA differs from most journals. Every paper that passes the desk goes through mandatory statistical review by dedicated statistical editors. This isn't a box-checking exercise. JAMA's statisticians are aggressive reviewers who will challenge your analytical choices, question your sample size justification, and flag any deviation from your pre-specified analysis plan.

What they're looking for:

• Reporting guideline compliance. CONSORT for RCTs, STROBE for observational studies, PRISMA for systematic reviews, STARD for diagnostic accuracy studies. If your CONSORT checklist has items marked "not applicable" that clearly are applicable, they'll catch it.

• Pre-registration consistency. If your trial is registered on ClinicalTrials.gov, the statistical editors will compare your registered primary endpoint to what you actually report. Endpoint switching without transparent disclosure is a rejection trigger.

• Multiplicity corrections. Multiple comparisons without adjustment, subgroup analyses that weren't pre-specified, and secondary analyses presented as primary findings, these are all common reasons for statistical rejection.

• Effect size reporting. P-values alone won't cut it. JAMA expects confidence intervals, and ideally absolute risk differences alongside relative measures. A hazard ratio of 0.75 means nothing without context about baseline risk.

The statistical review typically happens in parallel with clinical peer review, so it doesn't add extra time. But it can generate an entirely separate set of revision requests. You might get clinical reviewers saying the paper is great while the statistical editor asks for a completely different analytical approach.

JAMA's submission portal has several requirements that trip up first-time submitters:

Cover letter specifics. JAMA wants you to state explicitly which article type you're submitting, confirm that the work hasn't been published or submitted elsewhere, and disclose any related manuscripts under consideration at other journals. They also want you to suggest 3-5 reviewers and identify any conflicted reviewers to exclude. Don't skip the reviewer suggestions, editors actually use them.

ICMJE disclosure forms. Every author needs to complete an ICMJE conflict of interest form. Not just the corresponding author. Every single one. For a paper with 15 authors, this is logistically painful, and it's one of the most common reasons for administrative delays.

Data sharing statement. For clinical trials, JAMA requires a data sharing statement at submission, not just at acceptance. You'll need to specify what data will be shared, when, and with whom. This can't be vague, "data available upon reasonable request" without further specifics isn't sufficient anymore.

Author contributions using CRediT. JAMA expects author contributions mapped to CRediT taxonomy roles. If you've been using free-text author contribution statements, you'll need to reformat.

JAMA doesn't have formal submission windows, but timing still matters. Submission volume tends to spike after major conference seasons (ASCO, AHA, AACR) as researchers rush to publish presented findings. If you can submit during quieter periods, your paper may get slightly more editorial attention during triage.

Also worth knowing: JAMA has a rapid review track for time-sensitive research, particularly public health emergencies, urgent clinical safety signals, and rapidly evolving treatment landscapes. If your work genuinely qualifies, mention this in your cover letter.

A JAMA manuscript fit check at this stage can identify scope mismatches and common structural issues before you finalize your submission.

Not every good paper belongs in JAMA, and that's fine. The JAMA Network has 13 specialty journals, and a rejection from the flagship often comes with an offer to transfer your paper, including reviewer reports, to a more appropriate JAMA Network journal. JAMA Network Open has become an especially strong destination for rigorous studies that don't quite reach the flagship's significance threshold.

Before submitting, honestly assess whether your work speaks to general medicine or to a specialty audience. If it's really a cardiology paper, JAMA Cardiology might be a better initial target than the flagship. You won't lose prestige, and you'll save months.

A JAMA article type, formatting, and statistical reporting check can help you identify whether your article type choice, formatting, and statistical reporting align with JAMA's specific requirements before you enter the queue.

For manuscripts targeting JAMA (Journal of the American Medical Association), five patterns generate the most consistent desk rejections worth knowing before submission.

The observational association without clinical meaningfulness (~35%). In our experience, roughly 35% of desk rejections we see from JAMA-bound manuscripts involve studies that identify a statistically significant association but fail to place it in clinical context. JAMA's author guidelines require that effect sizes be framed through absolute risk differences and number needed to treat, not p-values alone. Editors consistently reject papers where the association is real but the clinical relevance of the effect size is never established.

The surrogate endpoint trial (~25%). In our experience, roughly 25% of rejected clinical trial manuscripts fail JAMA's surrogate endpoint standard. Papers claiming benefit on biomarkers without a validated connection to mortality or quality of life are treated as incomplete by JAMA editors. Editors consistently apply this standard rigorously; a statistically significant improvement in a surrogate does not satisfy the journal's evidence threshold unless the surrogate has been validated as a predictor of patient-relevant outcomes.

The meta-analysis that confirms what is already known (~20%). In our experience, roughly 20% of rejected systematic reviews and meta-analyses are declined because they do not resolve genuine clinical uncertainty. JAMA expects meta-analyses to answer a question that practicing clinicians are actually uncertain about; papers that synthesize a literature where the answer was already reasonably clear face desk rejection regardless of methodological quality. Editors consistently ask whether the synthesis changes anything a clinician would do.

The diagnostic accuracy paper without clinical impact assessment (~15%). In our experience, roughly 15% of rejected diagnostic papers fail because sensitivity and specificity are reported without demonstrating whether the test result changes treatment decisions. JAMA treats papers reporting test performance metrics without clinical impact assessment as incomplete for its standards. Editors consistently expect authors to show that the diagnostic information affects management, not just that the test performs well statistically.

The health policy paper without actionable recommendations (~10%). In our experience, roughly 10% of rejected health policy and economics submissions are declined because findings are descriptive without connecting to specific, actionable policy recommendations. JAMA publishes health policy research oriented toward changing clinical practice or health systems. Editors consistently screen for whether the analysis can drive a real decision, not whether it documents a problem.

SciRev community data for JAMA (Journal of the American Medical Association) confirms the review timeline and rejection patterns documented above.

Before submitting to JAMA, a JAMA submission readiness check identifies whether your study design, effect size framing, and endpoint selection meet JAMA's editorial bar before you commit to the submission.

Use these adjacent readiness checks when the target journal is still being chosen:

• Is My Paper Ready for JACS

• Is My Paper Ready for Science Advances

• Is My Paper Ready for Lancet

• Is My Paper Ready for Neuron

• Is My Paper Ready for Nature Methods

• Is My Paper Ready for Molecules

• Is My Paper Ready for IEEE Access

• Is My Paper Ready for Physical Review D

• Is My Paper Ready for Physical Review Letters

• Is My Paper Ready for Molecular Systems Biology

This page was built from JAMA's official Instructions for Authors, the JAMA journal homepage, JAMA Network article-type guidance, Clarivate context, and Manusights pre-submission review patterns from medical manuscripts targeting JAMA, JAMA Network journals, The Lancet, BMJ, NEJM, and major specialty journals.

Source limitations: we did not submit a live test manuscript to the private JAMA portal. Use JAMA's official instructions for final upload mechanics, current article-type labels, disclosure forms, and portal fields. Use this page for the readiness decision before you spend that submission.

Source limitations: This Is Your Paper Ready for JAMA? Journal of the American Medical Association Checklist page combines official guidance where available, public publisher or product materials, and our review work for JAMA (Journal of the American Medical Association); it is an independent readiness screen, not official guidance from the journal, publisher, or service.

In our work, we observe that authors use JAMA (Journal of the American Medical Association) comparisons to decide whether they need writing support, editing, or submission-readiness judgment; this page keeps those jobs separate instead of treating every tool as a substitute.